4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform. The company designs customized adeno-associated virus, or AAV, vectors intended to deliver therapeutic payloads to specific tissues and disease areas with precision. Its current clinical development programs are concentrated in retina and pulmonology, reflecting a portfolio aimed at treating serious conditions through targeted gene delivery. In ophthalmology, the company is advancing therapies for retinal vascular diseases and other eye disorders, while its respiratory work includes programs for lung-directed treatment of genetic disease. 4D Molecular Therapeutics, Inc. plays a specialized role in the gene therapy market by combining vector engineering, tissue targeting, and disease-focused development to support next-generation genetic medicine candidates.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. David H. Kirn M.D.

Employees

196

Headquarters

EmeryVille, CA, United States

Website

www.4dmoleculartherapeutics.com